Showing 1 - 5 results of 5 for search 'Joan Besalduch', query time: 0.02s Refine Results
  1. 1
    Long-term hematologic reconstitution and clinical evaluation of autologous peripheral blood stem cell transplantation after cryopreservation of cells with 5% and 10% dimethylsulfoxide at −80°C in a mechanical freezer

    Long-term hematologic reconstitution and clinical evaluation of autologous peripheral blood stem cell transplantation after cryopreservation of cells with 5% and 10% dimethylsulfox... by Antonio Galmes, Antonio Gutiérrez, Antonia Sampol, Mariana Canaro, Miguel Morey, Julio Iglesias, Nuria Matamoros, María Antonia Duran, Andrés Novo, María Dolores Bea, Pilar Galán, Josep Balansat, Jordi Martínez, Joan Bargay, Joan Besalduch

    Published 2007-07-01
    Get full text
    Article
  2. 2
    Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin’s lymphoma. Results of the HDR-ALLO study – a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de Médula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

    Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin’s lymphoma. Results of the HDR-ALLO study – a prospective... by Anna Sureda, Carme Canals, Reyes Arranz, Dolores Caballero, Josep Maria Ribera, Mats Brune, Jacob Passweg, Rodrigo Martino, David Valcárcel, Joan Besalduch, Rafael Duarte, Angel León, Maria Jesus Pascual, Ana García-Noblejas, Lucia López Corral, Bianca Xicoy, Jordi Sierra, Norbert Schmitz

    Published 2012-02-01
    Get full text
    Article
  3. 3
    High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma

    High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma by Silvia Montoto, Carol Moreno, Eva Domingo-Doménech, Cristina Estany, Albert Oriol, Albert Altés, Joan Besalduch, Carme Pedro, Santiago Gardella, Lourdes Escoda, Antoni Asensio, Pilar Vivancos, Pilar Galán, Alberto Fernández de Sevilla, Josep M. Ribera, Javier Briones, Dolors Colomer, Elías Campo, Emili Montserrat, Armando López-Guillermo

    Published 2008-02-01
    Get full text
    Article
  4. 4
    Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease

    Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease by Laura Rosiñol, Ramón García-Sanz, Juan José Lahuerta, Miguel Hernández-García, Miquel Granell, Javier de la Rubia, Albert Oriol, Belén Hernández-Ruiz, Consuelo Rayón, Isabel Navarro, Juan Carlos García-Ruiz, Joan Besalduch, Santiago Gardella, Javier López Jiménez, Joaquín Díaz-Mediavilla, Adrián Alegre, Jesús San Miguel, Joan Bladé

    Published 2012-04-01
    Get full text
    Article
  5. 5
    Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study

    Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included... by Juan José Lahuerta, Maria Victoria Mateos, Joaquin Martínez-López, Carlos Grande, Javier de la Rubia, Laura Rosiñol, Anna Sureda, José García-Laraña, Joaquín Díaz-Mediavilla, Miguel T. Hernández-García, Dolores Carrera, Joan Besalduch, Felipe de Arriba, Albert Oriol, Lourdes Escoda, Javier García-Frade, Concepción Rivas-González, Adrían Alegre, Joan Bladé, Jesús F. San Miguel

    Published 2010-11-01
    Get full text
    Article

Search Tools: